Search form


Press Releases

Axcan Pharma to Present at Merrill Lynch Healthcare Conference in New York

Jan 27, 2004 - 12:00 ET

Axcan Pharma to Present at Merrill Lynch Healthcare Conference in New York

MONT SAINT-HILAIRE, Quebec--Axcan Pharma Inc. ("Axcan" or the "Company") today
announced that on February 4, 2004, David W. Mims, Executive Vice President and
Chief Operating Officer of the Company, will make a presentation at the Merrill
Lynch Healthcare Conference held in New York, NY. This presentation will take
place at 10:45 a.m. EST.

Interested parties can access the audio webcast of the presentation on the
Company's website at

Axcan is a leading specialty pharmaceutical company involved in the field of
gastroenterology.  The Company markets a broad line of prescription products
sold for the treatment of symptoms in a number of gastrointestinal diseases
and disorders such as inflammatory bowel disease, irritable bowel syndrome,
cholestatic liver diseases and complications related to cystic fibrosis.
Axcan's products are marketed by its own sales force in North America and Europe.
Its common shares are listed on the Toronto Stock Exchange under the symbol "AXP"
and on the NASDAQ National Market under the symbol "AXCA".

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995.

To the extent any statements made in this release contain information that is not
historical, these statements are essentially forward looking and are subject to risks
and uncertainties, including the difficulty of predicting FDA approvals, acceptance
and demand for new pharmaceutical products, the impact of competitive products and
pricing, new product development and launch, reliance on key strategic alliances,
availability of raw materials, the regulatory environment, fluctuations in operating
results and other risks detailed from time to time in the Company's filings with the
Securities and Exchange Commission.

INFORMATION:    David W. Mims
                Executive Vice President and Chief Operating Officer
                Axcan Pharma Inc.
                Tel: (205) 991-8085 ext. 223

or              Isabelle Adjahi
                Director, Investor Relations					
                Axcan Pharma Inc.
		Tel: (450) 467-2600 ext. 2000